Hypoglycaemia and its management in primary care setting
Open accessAbstract
Hypoglycaemia is common in patients with type 1 diabetes and type 2 diabetes and constitutes a major limiting factor in achieving glycaemic control among people with diabetes. While hypoglycaemia is defined as a blood glucose level under 70 mg/dL (3.9 mmol/L), symptoms may occur at higher blood glucose levels in individuals with poor glycaemic control. Severe hypoglycaemia is defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions to assure neurologic recovery. Hypoglycaemia is the most important safety outcome in clinical studies of glucose lowering agents. The American Diabetes Association Standards of Medical Care recommends that a management protocol for hypoglycaemia should be designed and implemented by every hospital, along with a clear prevention and treatment plan. A tailored approach, using clinical and pathophysiologic disease stratification, can help individualize glycaemic goals and promote new therapies to improve quality of life of patients. Data from recent large clinical trials reported low risk of hypoglycaemic events with the use of newer anti‐diabetic drugs. Increased hypoglycaemia risk is observed with the use of insulin and/or sulphonylureas. Vulnerable patients with T2D at dual risk of severe hypoglycaemia and cardiovascular outcomes show features of “frailty.” Many of such patients may be better treated by the use of GLP‐1 receptor agonists or SGLT2 inhibitors rather than insulin. Continuous glucose monitoring (CGM) should be considered for all individuals with increased risk for hypoglycaemia, impaired hypoglycaemia awareness, frequent nocturnal hypoglycaemia and with history of severe hypoglycaemia. Patients with impaired awareness of hypoglycaemia benefit from real‐time CGM. The diabetes educator is an invaluable resource and can devote the time needed to thoroughly educate the individual to reduce the risk of hypoglycaemia and integrate the information within the entire construct of diabetes self‐management. Conversations about hypoglycaemia facilitated by a healthcare professional may reduce the burden and fear of hypoglycaemia among patients with diabetes and their family members. Optimizing insulin doses and carbohydrate intake, in addition to a short warm up before or after the physical activity sessions may help avoiding hypoglycaemia. Several therapeutic considerations are important to reduce hypoglycaemia risk during pregnancy including administration of rapid‐acting insulin analogues rather than human insulin, pre‐conception initiation of insulin analogues, and immediate postpartum insulin dose reduction.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Sulfonylurea can cause hypoglycemia by increasing endogenous insulin that may also contribute to local interactions with glucagon counter-regulation during hypoglycemia.
“Sulfonylurea can cause hypoglycemia by increasing endogenous insulin that may also contribute to local interactions with glucagon counter-regulation during hypoglycemia [1, 17, 18].”
From Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus (2026) · cites this paper as [17]
Section 10 identifies sulfonylureas as insulin secretagogues associated with hypoglycemia, supporting the claim that they can cause hypoglycemia by increasing endogenous insulin. The passages on glucagon and counter-regulation do not link sulfonylurea-induced insulin secretion to local interactions with glucagon counter-regulation, so that mechanism is not supported by this copy. (LLM, conf=0.86)
Experimental — accuracy not yet measuredA longer duration of type 2 diabetes is associated with a diminished counter-regulatory response to hypoglycemia.
“A longer duration of type 2 diabetes is associated with a diminished counter-regulatory response to hypoglycemia [1, 17–21].”
From Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus (2026) · cites this paper as [17]
The section “Impaired Awareness of Hypoglycemia” reports that glucose counterregulation, mainly the glucagon response, was virtually absent in people with longstanding, insulin-treated type 2 diabetes. This supports the link with long disease duration, but the cited finding is limited to insulin-treated patients; the claim does not retain that qualifier. (LLM, conf=0.84)
Experimental — accuracy not yet measuredPhysiological symptoms due to hypoglycemia and ability to self-treat both decline with increasing age.
“Physiological symptoms due to hypoglycemia, and ability to self-treat both decline with increasing age [17, 22, 23].”
From Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus (2026) · cites this paper as [17]
Section 4, “Impaired Awareness of Hypoglycemia” (page unavailable), says repeated hypoglycemic events can diminish symptom warnings. It does not attribute that decline to increasing age. The passages on age-related symptoms and self-management do not establish that the ability to self-treat declines with age. (LLM, conf=0.78)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 161 · Cited by 21
Research works printed but not linked: 12
- [1]1. Kedia N. Diabetes Metab Syndrome Obes: Targets Ther. 2011;4:337-346.
- [2]2. Geller AI et al. JAMA Intern Med. 2014;174(5):678-686.
- [4]4. Frier BM. Nat Rev Endocrinol. 2014;10:711-722. References
- [11]11. Cahn A, Mosenzon A, Bhatt DL et al. Hypoglycemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study. Diabetes Obes Metab. 2017 Jul;19(7):1045-1050).
- [18]18. Selvin E. Epidemiologic Evidence Linking Hypoglycemia to the Heart and Brain. Presented at: Heart in Diabetes CME Conference; July 12-14, 2019 Philadelphia.
- [20]20. Frier B.M. Impaired Awareness of Hypoglycemia. In: Frier B.M., Fisher B.M., eds. Hypoglycemia in Clinical Diabetes. Chichester,U.K.: John Wiley and Sons, 2007; 14.
- [25]25. P. E. Cryer et al.: Hypoglycemia: The limiting factor in the glycaemic management 939, Diabetologia. 2002;45:937-948.
- [30]30. Geddes J., Schopman J.E., Zammitt N.N., Frier B.M. Prevalence of impaired awareness of hypoglycemia in adults with type 1 diabetes. Diabet Med 2008; 25:501-504 .
- [41]41. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group Ann Intern Med. 1998 Feb 1;128(3):165-75.
- [47]47. Glycemic Targets. American Diabetes Association Standards of Medical Care. Diabetes Care 2019;42(1):S61-S70.
- [91]91. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol 2016; 4: 893-902.
- [123]123. Persson B, Hansson U. Hypoglycemia in pregnancy. Baillieres Clin Endocrinol Metab 1993;7:731- 739. 126
- Authors
- Ibrahim, M., Baker, J., Cahn, A., Eckel, R. H., El Sayed, N. A., Fischl, A. H., Gaede, P., Leslie, R. D., Pieralice, S., Tuccinardi, D., Pozzilli, P., Richelsen, B., Roitman, E., Standl, E., Toledano, Y., Tuomilehto, J., Weber, S. L., & Umpierrez, G. E.
- Affiliations
- EDC Center for Diabetes Education McDonough Georgia USA
- Weill Cornell Medicine (US)
- Hadassah Medical Center (IL)
- University of Colorado Hospital (US)
- Joslin Diabetes Center Harvard Medical School Boston Massachusetts USA
- University of Chicago (US)
- Department of Cardiology and Endocrinology Slagelse Hospital Slagelse Denmark
- University of London (GB)
- Università Campus Bio-Medico (IT)
- Aarhus University Hospital (DK)
- Clalit Health Services (IL)
- Helmholtz Munich (DE)
- Rabin Medical Center (IL)
- University of Helsinki (FI)
- Prisma Health (US)
- Emory University (US)
- Corresponding author
- Ibrahim, Mahmoud
- ORCID
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2020-05-18
- Volume
- 36
- Issue
- 8
- Pages
- e3332-e3332
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W3018415043
- Cited by
- 21
- References
- 161
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 3
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes/Metabolism Research and Reviews (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, other-oa)
- Työväentutkimus Vuosikirja (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Steno Diabetes Center Aarhus
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- hypoglycemia, hypoglycemia management, type 1 diabetes, type 2 diabetes, severe hypoglycemia, hypoglycemia prevention, continuous glucose monitoring, nocturnal hypoglycemia, insulin, sulfonylureas, GLP-1 receptor agonists, SGLT2 inhibitors, frailty, diabetes self-management education, glycemic control, primary care
- MeSH terms
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Hypoglycemia, Hypoglycemic Agents, Primary Health Care, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review